Assessing the pharmacokinetic profile of the CamMedNP natural products database: an in silico approach
Tóm tắt
Drug metabolism and pharmacokinetic (DMPK) assessment has come to occupy a place of interest during the early stages of drug discovery today. Computer-based methods are slowly gaining ground in this area and are often used as initial tools to eliminate compounds likely to present uninteresting pharmacokinetic profiles and unacceptable levels of toxicity from the list of potential drug candidates, hence cutting down the cost of the discovery of a drug. In the present study, we present an in silico assessment of the DMPK profile of our recently published natural products database of 1,859 unique compounds derived from 224 species of medicinal plants from the Cameroonian forest. In this analysis, we have used 46 computed physico-chemical properties or molecular descriptors to predict the absorption, distribution, metabolism and elimination (ADME) of the compounds. This survey demonstrated that about 50% of the compounds within the Cameroonian medicinal plant and natural products (CamMedNP) database are compliant, having properties which fall within the range of ADME properties of >95% of currently known drugs, while >73% of the compounds have ≤2 violations. Moreover, about 72% of the compounds within the corresponding ‘drug-like’ subset showed compliance. In addition to the previously verified levels of ‘drug-likeness’ and the diversity and the wide range of measured biological activities, the compounds in the CamMedNP database show interesting DMPK profiles and, hence, could represent an important starting point for hit/lead discovery from medicinal plants in Africa.
Tài liệu tham khảo
Li JWH, Vederas JC: Drug discovery and natural products: end of an era or an endless frontier? Science 2009, 325: 161–165. 10.1126/science.1168243
Chin YW, Balunas MJ, Chai HB, Kinghorn AD: Drug discovery from natural sources. AAPS J 2006,8(2):E239-E253.
Newman DJ: Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J Med Chem 2008, 51: 2589–2599. 10.1021/jm0704090
Harvey AL: Natural products in drug discovery. Drug Discov Today 2008, 13: 894–901. 10.1016/j.drudis.2008.07.004
Koehn FE, Carter GT: The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005, 4: 206–220. 10.1038/nrd1657
Efange SMN: Natural products: a continuing source of inspiration for the medicinal chemist. In Advances in phytomedicine. Edited by: Iwu MM, Wootton JC. Amsterdam: Elsevier; 2002.
Butler MS: Natural products to drugs: natural product derived compounds in clinical trials. Nat Prod Rep 2005, 22: 162–195. 10.1039/b402985m
Wetzel S, Schuffenhauer A, Roggo S, Ertl P, Waldmann H: Cheminformatic analysis of natural products and their chemical space. Chimia Int J Chem 2007, 61: 355–360. 10.2533/chimia.2007.355
Grabowski K, Baringhaus K-H, Schneider G: Scaffold diversity of natural products: inspiration for combinatorial library design. Nat Prod Rep 2008, 25: 892–904. 10.1039/b715668p
Grabowski K, Schneider G: Properties and architecture of drugs and natural products revisited. Curr Chem Biol 2007, 1: 115–127.
Quinn RJ, Carroll AR, Pham MB, Baron P, Palframan ME, Suraweera L, Pierens GK, Muresan S: Developing a drug-like natural product library. J Nat Prod 2008, 71: 464–468. 10.1021/np070526y
Hodgson J: ADMET – turning chemicals into drugs. Nat Biotechnol 2001, 19: 722–726. 10.1038/90761
Navia MA, Chaturvedi PR: Design principles for orally bioavailable drugs. Drug Dev Today 1996, 1: 179–189. 10.1016/1359-6446(96)10020-9
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 1997, 23: 3–25. 10.1016/S0169-409X(96)00423-1
Lombardo F, Gifford E, Shalaeva MY: In silico ADME prediction: data, models, facts and myths. Mini Rev Med Chem 2003, 3: 861–875. 10.2174/1389557033487629
Gleeson MP, Hersey A, Hannongbua S: In-silico ADME models: a general assessment of their utility in drug discovery applications. Curr Top Med Chem 2011,11(4):358–381. 10.2174/156802611794480927
DiMasi JA, Hansen RW, Grabowsk HG: The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22: 151–185. 10.1016/S0167-6296(02)00126-1
Darvas F, Keseru G, Papp A, Dormán G, Urge L, Krajcsi P: In silico and ex silico ADME approaches for drug discovery. Top Med Chem 2002, 2: 1287–1304. 10.2174/1568026023392841
eADMET: OCHEM - our platform for the creation of in silico ADME/tox prediction models. 2011. . Accessed 21 June 2013 http://www.eadmet.com/en/ochem.php
Lhasa Ltd: Meteor, version 13.0.0. Leeds, UK: Lhasa Ltd; 2010.
Schrödinger: QikProp, version 3.4. New York, NY: LLC; 2011.
Cruciani C, Crivori P, Carrupt PA, Testa B: Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J Mol Struc-Theochem 2000, 503: 17–30. 10.1016/S0166-1280(99)00360-7
Tetko IV, Bruneau P, Mewes H-W, Rohrer DC, Poda GI: Can we estimate the accuracy of ADMET predictions? Drug Discov Today 2006, 11: 700–707. 10.1016/j.drudis.2006.06.013
Hansch C, Leo A, Mekapatia SB, Kurup A: QSAR and ADME. Bioorg Med Chem 2004, 12: 3391–3400. 10.1016/j.bmc.2003.11.037
Greene N, Judson PN, Langowski JJ: Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR QSAR Environ Res 1999, 10: 299–314. 10.1080/10629369908039182
Button WG, Judson PN, Long A, Vessey JD: Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics. J Chem Inf Comput Sci 2003, 43: 1371–1377. 10.1021/ci0202739
Cronin MTD: Computer-assisted prediction of drug toxicity and metabolism in modern methods of drug discovery. In Modern methods of drug discovery. Edited by: Hilgenfeld R, Hillisch A. Basel: Birkhäuser; 2003.
Hou T, Wang J: Structure-ADME relationship: still a long way to go? Expert Opin Drug Metab Toxicol 2008,4(6):759–770. 10.1517/17425255.4.6.759
Ntie-Kang F, Mbah JA, Mbaze LM, Lifongo LL, Scharfe M, Ngo Hanna J, Cho-Ngwa F, Amoa Onguéné P, Owono Owono LC, Megnassan E, Sippl W, Efange SMN: CamMedNP: building the Cameroonian 3D structural natural products database for virtual screening. BMC Complement Altern Med 2013, 13: 88. 10.1186/1472-6882-13-88
Ntie-Kang F, Lifongo LL, Mbaze LM, Ekwelle N, Owono Owono LC, Megnassan E, Judson PN, Sippl W, Efange SMN: Cameroonian medicinal plants: a bioactivity versus ethnobotanical survey and chemotaxonomic classification. BMC Complement Altern Med 2013, 13: 147. 10.1186/1472-6882-13-147
Chemical Computing Group, Inc: Molecular operating environment software. Montreal: CCG; 2010.
Halgren TA: Merck molecular force field. J Comput Chem 1996, 17: 490–641. 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
Schrödinger: LigPrep software, version 2.5. New York, NY: LLC; 2011.
Schrödinger: Maestro, version 9.2. New York, NY: LLC; 2011.
Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, Sherman W: Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput 2010, 6: 1509–1519. 10.1021/ct900587b
Jorgensen WL, Maxwell DS, Tirado-Rives J: Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 1996,118(45):11225–11236. 10.1021/ja9621760
Jorgensen WL, Tirado-Rives J: The OPLS (optimized potentials for liquid simulations) potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 1988,110(6):1657–1666. 10.1021/ja00214a001
Jorgensen WL, Duffy EM: Prediction of drug solubility from structure. Adv Drug Deliv Rev 2002, 54: 355–366. 10.1016/S0169-409X(02)00008-X
Duffy EM, Jorgensen WL: Prediction of properties from simulations: free energies of solvation in hexadecane, octanol, and water. J Am Chem Soc 2000, 122: 2878–2888. 10.1021/ja993663t
Jorgensen WL, Duffy EM: Prediction of drug solubility from Monte Carlo simulations. Bioorg Med Chem Lett 2000, 10: 1155–1158. 10.1016/S0960-894X(00)00172-4
Colmenarejo G, Alvarez-Pedraglio A, Lavandera J-L: Cheminformatic models to predict binding affinities to human serum albumin. J Med Chem 2001, 44: 4370–4378. 10.1021/jm010960b
Luco JM: Prediction of brain–blood distribution of a large set of drugs from structurally derived descriptors using partial least squares (PLS) modelling. J Chem Inf Comput Sci 1999, 39: 396–404. 10.1021/ci980411n
Kelder J, Grootenhuis PD, Bayada DM, Delbresine LP, Ploemen JP: Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 1999, 16: 1514–1519. 10.1023/A:1015040217741
Ajay BGW, Murkco MA: Designing libraries with CNS activity. J Med Chem 1999, 42: 4942–4951. 10.1021/jm990017w
Yazdanian M, Glynn SL, Wright JL, Hawi A: Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res 1998, 15: 1490–1494. 10.1023/A:1011930411574
Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR: MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 1999, 88: 28–33. 10.1021/js9803205
Stenberg P, Norinder U, Luthman K, Artursson P: Experimental and computational screening models for the prediction of intestinal drug absorption. J Med Chem 2001, 44: 1927–1937. 10.1021/jm001101a
Cavalli A, Poluzzi E, De Ponti F, Recanatini M: Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA Study of HERG K+ channel blockers. J Med Chem 2002, 45: 3844–3853. 10.1021/jm0208875
De Ponti F, Poluzzi E, Montanaro N: Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001, 57: 185–209. 10.1007/s002280100290
Potts RO, Guy RH: Skin permeability. Pharm Res 1992, 9: 663–669. 10.1023/A:1015810312465
Potts RO, Guy RH: A predictive algorithm for skin permeability: the effects of molecular size and hydrogen bond activity. Pharm Res 1995, 12: 1628–1633. 10.1023/A:1016236932339
Schrödinger Press: QikProp 3.4 user manual. New York, NY: LLC; 2011.
Teague SJ, Davis AM, Leeson PD, Opea TI: The design of leadlike combinatorial libraries. Angew Chem Int Ed 1999, 38: 3743–3748. 10.1002/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.0.CO;2-U
Oprea TI: Current trends in lead discovery: are we looking for the appropriate properties? J Comput-Aided Mol Des 2002, 16: 325–334. 10.1023/A:1020877402759
Schneider G: Trends in virtual computational library design. Curr Med Chem 2002, 9: 2095–2102. 10.2174/0929867023368755
Verdonk ML, Cole JC, Hartshorn ML, Murray CW, Taylor RD: Improved protein-ligand docking using GOLD. Proteins 2003, 52: 609–623. 10.1002/prot.10465
Van de Waterbeemd H, Gifford E: ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2003, 2: 192–204. 10.1038/nrd1032
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD: Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002, 45: 2615–2623. 10.1021/jm020017n
Hedley PL, Jørgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, Corfield VA, Christiansen M: The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat 2009, 30: 1486–1511. 10.1002/humu.21106
Vandenberg JI, Walker BD, Campbell TJ: HERG K+ channels: friend or foe. Trends Pharmacol Sci 2001, 22: 240–246. 10.1016/S0165-6147(00)01662-X
Chiesa N, Rosati B, Arcangeli A, Olivotto M, Wanke E: A novel role for HERG K+ channels: spike-frequency adaptation. J Physiol 1997, 501: 313–318. 10.1111/j.1469-7793.1997.313bn.x
Aronov AM: Predictive in silico modeling for hERG channel blockers. Drug Discov Today 2005, 10: 149–155. 10.1016/S1359-6446(04)03278-7
Chibale K, Davies-Coleman M, Masimirembwa C: Drug discovery in Africa: impacts of genomics, natural products, traditional medicines, insights into medicinal chemistry, and technology platforms in pursuit of new drugs. Berlin: Springer; 2012.
pan-ANAPL: pan-African Natural Products Library. Accessed 21 June 2013 http://www.linkedin.com/groups/pANPL-4098579/about]